StreetInsider.com News Articles

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Mon, 02 Mar 2026 09:10:00 -0500

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Mon, 02 Mar 2026 09:10:00 -0500

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Mon, 02 Mar 2026 09:10:00 -0500

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Mon, 02 Mar 2026 09:10:00 -0500

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Mon, 23 Feb 2026 08:55:00 -0500

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

Form 8-K Anixa Biosciences Inc For: Feb 09

Mon, 09 Feb 2026 08:03:00 -0500

si-local-file:///var/storage/secattach/20260209/25965170.html

Form 8-K Anixa Biosciences Inc For: Feb 09

Mon, 09 Feb 2026 08:03:00 -0500

si-local-file:///var/storage/secattach/20260209/25965170.html

Anixa gets approval to increase CAR-T doses up to 100x in cancer trial

Mon, 09 Feb 2026 08:02:55 -0500

Anixa Biosciences Inc. (NASDAQ: ANIX) received regulatory approval to escalate doses in its ovarian cancer CAR-T trial by up to 100 times the original levels, the company announced February 9.

The biotechnology company reported that 12 patients have been treated at four dosage levels in the Phase 1 trial. Seven patients have exceeded expected median survival of three to four months based on disease stage and prior therapy history. One patient survived 28 months following treatment, while three patients have survived greater than one year at 17, 15 and 14 months respectively.

The trial has not observed dose-limiting toxicities to date, prompting

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation